NOVO_B: Record Wegovy pill launch drives patient growth, but 2026 outlook faces price-driven headwinds
Less than 1 min read
Sales and profit more than doubled over five years, with strong cash conversion and a record Wegovy pill launch. 2026 guidance reflects price-driven top-line decline, offset by disciplined cost management and continued volume growth, amid a dynamic and competitive obesity market.
Based on Novo Nordisk A/S Class B [NOVO_B] Q4 2025 London conference call Audio Transcript — Feb. 5 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr